RecruitingType 2 Diabetes Mellitus (T2DM)Non-Alcoholic Fatty Liver Disease (NAFLD)
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
Eligible age
18–64 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose. In addition, the preliminary effects of QX1206 on antidiabetic activity and other metabolic parameters will also be evaluated.
Sponsor: 1Globe Health Institute
You may qualify if…
- ✓ Signed written informed consent must be obtained and documented
- ✓ 18 years of age and \< 65 years old
- ✓ BMI ≥ 18 kg/m\^2 and \< 45 kg/m\^2
- ✓ T2DM diagnosed per 2021 American Diabetes Association criteria
- ✓ Diagnosis of NAFLD
- ✓ For male or female patients of child producing potential: must agree to use contraception or take measures to avoid pregnancy during the study
- ✓ Women of child-bearing potential (WOCBP) must have a negative pregnancy test
- ✓ Serum creatinine \< 1.5×ULN or creatinine clearance ≥ 60 ml/min
You may not qualify if…
- ✕ Uncontrolled diabetes
- ✕ Patients with an active, serious medical disease that limit activities of daily living
- ✕ Patients with current, significant alcohol consumption or a history of significant alcohol consumption
- ✕ Patients with any of the following clinical laboratory abnormalities at screen and confirmed by a single repeat if deemed necessary:
- ✕ Fasting triglycerides \> 500 mg/dL
- ✕ Fasting direct LDL-C \> 190 mg/dL
- ✕ AST \> 5.0 × upper limit of normal (ULN)
- ✕ ALT \> 5.0 × ULN
Source: ClinicalTrials.gov · NCT06694935 · last updated 2025-01-13